Menu Search
Equities

Exact Sciences Corp

EXK:STU

Exact Sciences Corp

Actions
  • Price (EUR)55.34
  • Today's Change0.49 / 0.89%
  • Shares traded0.00
  • 1 Year change-2.11%
  • Beta--
Data delayed at least 15 minutes, as of Apr 30 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

  • Revenue in USD (TTM)2.50bn
  • Net income in USD-204.15m
  • Incorporated1995
  • Employees6.50k
  • Location
    Exact Sciences Corp5505 Endeavor LaneMADISON 53719United StatesUSA
  • Phone+1 (608) 284-5700
  • Fax+1 (608) 284-5701
  • Websitehttps://www.exactsciences.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		EXAS:NAQ since
announced		Transaction
value
Resolution Bioscience IncAnnounced12 Sep 202312 Sep 2023Announced-24.77%--
Data delayed at least 15 minutes, as of May 01 2024 21:15 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.